Fang Liu

发表

Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

R. Conley, D. Kelly, Kimberly R. Warren, 2013, Journal of Clinical Psychopharmacology.

Blood Draw Barriers for Treatment with Clozapine and Development of a Point-of-Care Monitoring Device.

Eunkyoung Kim, G. Payne, D. Kelly, 2015, Clinical schizophrenia & related psychoses.

An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients

Rajendra P. Shukla, D. Kelly, H. Ben‐Yoav, 2020 .

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2009, The Journal of clinical psychiatry.

Diagnostic criteria for cannabis withdrawal syndrome.

D. Kelly, D. Boggs, S. Heishman, 2012, Drug and alcohol dependence.

25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia.

Megan M. Powell, D. Kelly, H. Wehring, 2022, Journal of psychiatric research.

Cannabis withdrawal in chronic cannabis users with schizophrenia.

D. Kelly, D. Boggs, D. Gorelick, 2013, Journal of psychiatric research.

Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder

D. Kelly, H. Wehring, Kimberly R. Warren, 2013, Schizophrenia Research.

Intelligent Multi-Electrode Array for Real-Time Treatment Monitoring of Antipsychotic Clozapine

Rajendra P. Shukla, D. Kelly, H. Ben‐Yoav, 2020 .

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels

D. Kelly, H. Wehring, S. Feldman, 2018, Psychiatric Quarterly.

L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia

D. Kelly, H. Wehring, S. Hoag, 2020, Schizophrenia Bulletin Open.

Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Megan M. Powell, D. Kelly, H. Wehring, 2019, Journal of psychiatry & neuroscience : JPN.

Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia

S. A. Wijtenburg, D. Kelly, L. Rowland, 2017, Front. Psychiatry.

Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.

D. Kelly, D. Boggs, S. Heishman, 2010, Drug and alcohol dependence.

Clinical characteristics of heavy and non-heavy smokers with schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia.

D. Kelly, H. Wehring, S. Feldman, 2012, Schizophrenia bulletin.

Cigarette smoking and mortality risk in people with schizophrenia.

D. Kelly, R. McMahon, H. Wehring, 2011, Schizophrenia bulletin.

Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.

D. Kelly, M. Huestis, D. Gorelick, 2013, Journal of analytical toxicology.

Increased circulating regulatory T cells in medicated people with schizophrenia

D. Kelly, S. Feldman, R. Buchanan, 2018, Psychiatry Research.

Tobacco craving in smokers with and without schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2011, Schizophrenia Research.

Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness

D. Kelly, H. Wehring, R. Love, 2022, Schizophrenia Research.

Illicit drug use in heavy smokers with and without schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial

Megan M. Powell, F. Dickerson, D. Kelly, 2018, Journal of clinical psychopharmacology.

Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia

D. Kelly, L. Rowland, Matthew Glassman, 2017, Schizophrenia Research.

Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2017, Journal of dual diagnosis.

The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G.

Megan M. Powell, D. Kelly, H. Wehring, 2020, Journal of clinical psychopharmacology.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms

D. Kelly, H. Wehring, S. Feldman, 2015, Journal of clinical psychopharmacology.

Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial

R. Conley, D. Kelly, D. Boggs, 2012, Schizophrenia Research.

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

R. Conley, D. Kelly, H. Wehring, 2011, Journal of clinical psychopharmacology.

Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia

D. Kelly, H. Wehring, R. Love, 2019, Psychiatric Quarterly.

Blinded Clinical Ratings of Social Media Data are Correlated with In-Person Clinical Ratings in Participants Diagnosed with Either Depression, Schizophrenia, or Healthy Controls

Megan M. Powell, P. Resnik, D. Kelly, 2020, Psychiatry Research.

Serum amyloid P component level is associated with clinical response to escitalopram treatment in patients with major depressive disorder.

G. Wang, A. Wong, Jian Yang, 2021, Journal of psychiatric research.

Schizophrenia clinical symptom differences in women vs. men with and without a history of childhood physical abuse

D. Kelly, S. Feldman, L. Rowland, 2016, Child and Adolescent Psychiatry and Mental Health.

Peripheral Cortisol and Inflammatory Response to a Psychosocial Stressor in People with Schizophrenia

D. Kelly, H. Wehring, L. Rowland, 2018, Journal of neuropsychiatry.

The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report

D. Kelly, H. Wehring, R. Buchanan, 2019, Journal of psychiatry and brain science.

Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study

D. Kelly, H. Wehring, R. Buchanan, 2013, Schizophrenia Research.

Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia

D. Kelly, H. Wehring, R. Buchanan, 2016, Schizophrenia Research.

Exercise Program Adherence Using a 5-Kilometer (5K) Event as an Achievable Goal in People With Schizophrenia

D. Kelly, Kimberly R. Warren, S. Feldman, 2011, Biological research for nursing.

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Journal of psychiatric research.

Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study

D. Kelly, R. Buchanan, Alison S Buchholz, 2011, Schizophrenia Research.

Effects of intranasal oxytocin on satiety signaling in people with schizophrenia

D. Kelly, H. Wehring, Kimberly R. Warren, 2018, Physiology & Behavior.

Prebiotic Treatment Increases Serum Butyrate in People With Schizophrenia

D. Kelly, R. Buchanan, M. Kane, 2021, Journal of clinical psychopharmacology.

Blood Pressure and Heart Rate Changes During Clozapine Treatment

F. Liu, D. Kelly, S. Feldman, 2017, Psychiatric Quarterly.

Subjective and Physiological Effects After Controlled Sativex and Oral THC Administration

M. Huestis, F. Liu, S. Wright, 2011, Clinical pharmacology and therapeutics.

Antagonist-Elicited Cannabis Withdrawal in Humans

D. Kelly, M. Huestis, D. Gorelick, 2011, Journal of clinical psychopharmacology.

Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial

D. Kelly, H. Wehring, R. Love, 2023, Schizophrenia Research.

Illicit drug use in heavy smokers with and without schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.